He has served on speakers bureaus for Pfizer Inc., Wyeth Pharmaceuticals and Schering Plough Corporation and has received research and/or grant support from Astra Zeneca, Boehringer Ingelheim, www.selleckchem.com/products/nutlin-3a.html Bristol Myers-Squibb, Cephalon, Dainippon, Eli Lilly, Forest, Lundbeck, Novartis, PamLabs,

Pfizer, Pfizer Canada, Pharmasquire, Sanofi Aventis, Schering Plough, Inhibitors,research,lifescience,medical Shire, and Wyeth.
Attention deficit hyperactivity disorder (ADHD) is defined in the Diagnostic and Statistical Manual of Mental Disorders (DSM-IV) [American Psychiatric Association, 1994] as a clinical syndrome presenting with ‘high levels of inattentive and/or hyperactive and impulsive behaviours in Inhibitors,research,lifescience,medical early childhood that persist over time, pervade

across situations, and lead to notable impairments’. Others [Rowland et al. 2002] define ADHD as the most common neurodevelopmental disorder of childhood and, as such, ADHD is a common disorder. In the UK, a survey of 10,438 children between the ages of 5 and 15 found that 3.62% of boys and 0.85% of girls had ADHD [Ford et al. 2003]. In adults, the prevalence is reported Inhibitors,research,lifescience,medical to be from 2.9% [Faraone and Biederman, 2005] to 4.4% [Kessler et al. 2006]. For ADHD, it is the case that patients will be transferred from children’s health services to adult services around the age of 18. The National Institute for Clinical Excellence (NICE), went as far as recommending models of how this should take place [National Institute for Health and Clinical Excellence, 2008a] and the concept of a transitional process [Department of Health, 2006] has been well articulated by policy makers. However, despite the belief that the policy initiatives outlined above are Inhibitors,research,lifescience,medical moving on well [Department

of Health, 2008], the fact on the Tubacin structure ground for ADHD is that they are not moving well at all Inhibitors,research,lifescience,medical [Singh, 2009]. The main reason for this is the not only the general lack of services for adults with ADHD in the UK [Tettenborn et al. 2008; Verity and Coates, 2007], but the disparity among providers on the use of transitional protocols for adults with ADHD [Singh et al. 2008]. As a consequence of this disparity, apart from the potentially negative effects on the clinical care of adults with ADHD, there is the lack of UK relevant transitional data to inform service development. This paper aims to begin to bridge that gap by providing AV-951 information on one of the aims of the transition process which is the review of medication. Method All patients in transition from adolescence to adulthood referred from their general practitioner, paediatrician or child and adolescent psychiatrist to the Yorkshire service for adults with ADHD between June 2009 and February 2010 were included. The transitional protocol was not yet in place during this time and therefore the process of transfer was of hand-over.